Hematologic

The course illustrates the global view of Radiation for Hematologic Malignancies via the following abstracts:

  • Assessing the Role of Radiation Therapy for Primary Mediastinal Large B-Cell Lymphoma in the Setting of PET Avid Disease after Chemotherapy
  • An Excess Mortality Risk Analysis of Proton Beam versus Optimal Photon Radiotherapy for Mediastinal Hodgkin Lymphoma: Who May Benefit Most?
  • Efficacy of Low Dose Radiotherapy in Head & Neck MALT Lymphoma
  • A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma
  • Is Bridging Radiation (RT) Safe with B Cell Maturation Antigen–targeting Chimeric Antigenic Receptor T Cells (CART-BCMA) Therapy?
  • Bridging Radiotherapy before CAR-T for High Grade Lymphoma ― Feasibility and Efficacy
  • Effective Pain Control with Very Low Dose Palliative Radiotherapy for Multiple Myeloma Patients with Painful Osseous Lesions
  • Radiation Therapy for Refractory High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

 

Target Audience

The course is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, and all other health professionals involved in the field of radiation oncology.

Learning Objectives

Upon completion of this activity, learners should be able to do the following:

  • Determine how to use PET/CT responses to decide which patients with PMBCL may need adjuvant therapy.
  • Discuss how radiation target overlap with the heart can impact the decision to refer for proton therapy in Hodgkin lymphoma.
  • Explain the different dose regimens in use for MALT lymphomas, and how auto-immune disease may impact this.
  • Describe the evolving role of radiation therapy in CAR T-cell therapy in hematologic malignancies.
  • Describe the pain response with low dose RT for myeloma.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
01/01/2021
Course expires: 
12/31/2023
Cost:
$0.00
Parent activity set: 
Rating: 
0

Hematologic
John Plastaras, MD, PhD is employed by University of Pennsylvania and has no other disclosures to declare.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.